XTX Topco Ltd Sells 223,267 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

XTX Topco Ltd lessened its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 87.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 31,782 shares of the company’s stock after selling 223,267 shares during the period. XTX Topco Ltd’s holdings in Xeris Biopharma were worth $72,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in XERS. Simplicity Wealth LLC bought a new stake in shares of Xeris Biopharma in the 2nd quarter valued at about $27,000. Bayesian Capital Management LP acquired a new position in Xeris Biopharma in the first quarter valued at about $37,000. Allspring Global Investments Holdings LLC raised its position in shares of Xeris Biopharma by 4,512.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after purchasing an additional 15,929 shares during the period. Quarry LP bought a new position in shares of Xeris Biopharma during the 4th quarter valued at about $47,000. Finally, Eagle Asset Management Inc. acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at approximately $48,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $2.79 on Wednesday. The stock has a 50 day moving average price of $2.66 and a 200 day moving average price of $2.28. The stock has a market capitalization of $413.63 million, a PE ratio of -5.94 and a beta of 2.76. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.46 and a 52 week high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The business had revenue of $48.07 million during the quarter, compared to analysts’ expectations of $46.80 million. During the same period last year, the business earned ($0.14) earnings per share. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.